NASDAQ:AKER Akers Biosciences (AKER) Stock Price, News & Analysis → Better than Bitcoin? The Biotech Stock with 46,751% Potential (From Behind the Markets) (Ad) Free AKER Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range$2.74▼$2.8850-Day Range$2.47▼$4.5952-Week Range$1.65▼$6.97Volume17,428 shsAverage Volume769,876 shsMarket Capitalization$47.29 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisCompetitorsHeadlinesSocial MediaStock AnalysisCompetitorsHeadlinesSocial Media Get Akers Biosciences alerts: Email Address Ad Weiss RatingsProtect Yourself While There’s Still Time …The next step of the Fed's control is here. Section 702 of the Foreign Intelligence Surveillance Act was renewed for two more years and passed into law earlier this week. Allowing the Fed to tighten its grip on your personal privacy and freedom.4 simple steps to protect your privacy and money before it’s too late. About Akers Biosciences Stock (NASDAQ:AKER)Akers Biosciences, Inc. focuses on the development of a vaccine candidate against SARS-CoV-2, a coronavirus causing a pandemic. It has a collaboration agreement with Premas Biotech PVT Ltd. The company was incorporated in 1989 and is headquartered in New York, New York.Read More Ad Weiss RatingsProtect Yourself While There’s Still Time …The next step of the Fed's control is here. Section 702 of the Foreign Intelligence Surveillance Act was renewed for two more years and passed into law earlier this week. Allowing the Fed to tighten its grip on your personal privacy and freedom.4 simple steps to protect your privacy and money before it’s too late. AKER Stock News HeadlinesApril 16, 2024 | msn.comSpringfield Police Superintendent Akers looks to connect with youthApril 10, 2024 | msn.comLawrence Akers sworn-in as Springfield’s next police superintendentApril 27, 2024 | Weiss Ratings (Ad)Protect Yourself While There’s Still Time …The next step of the Fed's control is here. Section 702 of the Foreign Intelligence Surveillance Act was renewed for two more years and passed into law earlier this week. Allowing the Fed to tighten its grip on your personal privacy and freedom.April 10, 2024 | msn.comOil spillage on Akers Way after bus crash closes roadMarch 25, 2024 | msn.comBetsy Akers reveals $35M Tuxedo Park mansion as her priciest listing yetMarch 21, 2024 | msn.comWoman charged with causing death of teenager on Akers WayMarch 13, 2024 | msn.comCam Akers Becomes A Free AgentMarch 7, 2024 | msn.comRugby Almanack editor Clive Akers steps down after 30 years at rugby book of recordApril 27, 2024 | Weiss Ratings (Ad)Protect Yourself While There’s Still Time …The next step of the Fed's control is here. Section 702 of the Foreign Intelligence Surveillance Act was renewed for two more years and passed into law earlier this week. Allowing the Fed to tighten its grip on your personal privacy and freedom.February 6, 2024 | msn.comAkers Mill reopens, Powers Island unit closed at Chattahoochee River parkJanuary 23, 2024 | health.usnews.comJennifer C. AkersJanuary 17, 2024 | msn.comWill the Vikings Bring Back Restricted Free Agent RB Cam Akers in 2024?January 15, 2024 | msn.comDeputy Chief Lawrence Akers to become next Springfield Police SuperintendentJanuary 9, 2024 | msn.comJB Akers appointed to West Virginia House of DelegatesDecember 11, 2023 | msn.comTom Akers, Lewis Knudsen to perform holiday showNovember 16, 2023 | axios.comChloe Akers: Bringing politics back to the middleNovember 12, 2023 | msn.comCam Akers fined more for 'taunting' than Falcons player was for vicious hitNovember 11, 2023 | msn.comThe NFL fined Cam Akers on the week he tore his Achilles once againNovember 9, 2023 | msn.comWhen Is Cam Akers Coming Back? Fantasy Football Injury Return UpdateNovember 8, 2023 | msn.comCam Akers Dynasty Value: What Is the Vikings RB’s Value Now After His Injury?November 8, 2023 | msn.comVikings put Cam Akers on IR, sign QB Tanner Morgan to practice squadNovember 8, 2023 | cbsnews.comVikings place RB Cam Akers on IR, re-sign QB Tanner Morgan to practice squadNovember 6, 2023 | msn.comFormer Rams running back Cam Akers feared to have torn his Achilles Sunday vs. FalconsNovember 6, 2023 | msn.comCam Akers injures Achilles, could be done for seasonNovember 6, 2023 | msn.comLos Angeles Rams Ex Cam Akers Out For Season With Torn Achilles - Injury TrackerNovember 6, 2023 | msn.comFormer Rams RB Cam Akers tears Achilles for 2nd time in less than 3 yearsNovember 6, 2023 | msn.comVikings lose RB Cam Akers for rest of season because of Achilles tendon ruptureSee More Headlines Receive AKER Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Akers Biosciences and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/15/2018Today4/27/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Diagnostic Substances Sub-IndustryN/A Current SymbolNASDAQ:AKER CUSIPN/A CIK1321834 Webwww.akersbio.com Phone856 848 8698FaxN/AEmployees4Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-3,890,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-87.42% Return on Assets-73.31% Debt Debt-to-Equity RatioN/A Current Ratio9.22 Quick Ratio9.22 Sales & Book Value Annual Sales$1.58 million Price / Sales29.93 Cash FlowN/A Price / Cash FlowN/A Book Value$5.38 per share Price / Book0.53Miscellaneous Outstanding Shares16,653,000Free FloatN/AMarket Cap$47.29 million OptionableNot Optionable Beta0.30 A Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for May 2024. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.Get This Free Report Key ExecutivesMr. Christopher C. Schreiber (Age 56)CEO, Pres & Director Comp: $507.62kMr. Ian Rhodes (Age 48)Interim Chief Financial Officer Mr. Gary M. Rauch (Age 65)VP of Fin. & Treasurer Key CompetitorsAspira Women's HealthNASDAQ:AWHImmuCellNASDAQ:ICCCARCA biopharmaNASDAQ:ABIOOncoCyteNASDAQ:OCXCardio DiagnosticsNASDAQ:CDIOView All Competitors AKER Stock Analysis - Frequently Asked Questions How were Akers Biosciences' earnings last quarter? Akers Biosciences, Inc. (NASDAQ:AKER) released its earnings results on Thursday, November, 15th. The medical instruments supplier reported ($0.26) earnings per share (EPS) for the quarter. The medical instruments supplier earned $0.56 million during the quarter. What is Thomas A. Nicolette's approval rating as Akers Biosciences' CEO? 3 employees have rated Akers Biosciences Chief Executive Officer Thomas A. Nicolette on Glassdoor.com. Thomas A. Nicolette has an approval rating of 64% among the company's employees. What other stocks do shareholders of Akers Biosciences own? Based on aggregate information from My MarketBeat watchlists, some companies that other Akers Biosciences investors own include ImmunoGen (IMGN), Sorrento Therapeutics (SRNE), AVEO Pharmaceuticals (AVEO), Advanced Micro Devices (AMD), Aytu BioPharma (AYTU), Biopharmx (BPMX), Neovasc (NVCN), Micron Technology (MU), Vaxart (VXRT) and Anavex Life Sciences (AVXL). This page (NASDAQ:AKER) was last updated on 4/27/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThese AI trades triggered this morning (545% return)Prosper Trading AcademyHe Is Giving Away BitcoinCrypto Swap ProfitsThe A.I. story nobody is telling you (Read ASAP)TradeSmithFed launches fourth dollar overhaulStansberry ResearchBiden out June 13; Kamala won’t replace him?Paradigm PressMan Who Predicted 2008: “This Will be Worse.”AltimetryExposed: 10 CENT Crypto to Explode April 20th?True Market Insiders Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Akers Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
